Athira Pharma Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Athira Pharma Provides 2024 Clinical Pipeline Outlook And Business Update
Brief: Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
U.S. RESEARCH ROUNDUP- Compass Minerals International, Equinix, Kingstone Companies
Brief: Athira Pharma Q3 EPS USD -0.87
Athira Pharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Athira Pharma Q2 EPS USD -0.78
Brief: Athira Pharma Appoints Andrew Gengos As CFO And Chief Business Officer
Athira Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Athira Pharma Reports First Quarter 2023 Financial Results And Recent Pipeline And Business Updates
Athira Pharma Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Athira Pharma Presents New Clinical And Preclinical Data
U.S. RESEARCH ROUNDUP-Globus Medical, Philip Morris, Vail Resorts
U.S. RESEARCH ROUNDUP-Globus Medical, Philip Morris International, Vail Resorts
U.S. RESEARCH ROUNDUP- General Mills, McDonald's, Wells Fargo & Co
Brief: Athira Pharma Reports Full Year 2022 Financial Results And Recent Pipeline And Business Updates
Athira Pharma Inc reports results for the quarter ended in December - Earnings Summary
Athira Pharma Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Athira Pharma Files For Offering Of Up To $75 Million Common Stock- SEC Filing